About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $5.58 | Open | $5.62 |
Volume | 4.83M | Market Cap | 591.64M |
Yield | Last Dividend |
Understanding Clovis Oncology's Unusual ... | 03/02/21 |
Shares of Clovis Oncology (NASDAQ:CLVS) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down t... |
Thinking about buying stock in Workhorse... | 02/25/21 |
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, SNDL, NOK, CLVS, and CGEN. To see how InvestorsO... |
Clovis Oncology (NASDAQ:CLVS) Issues Ear... | 02/24/21 |
Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.02) EPS for the quarter, mis... |
Clovis Oncology Announces 2020 Operating... | 02/23/21 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, ... |
Earnings Preview for Clovis Oncology | 02/22/21 |
Clovis Oncology (NASDAQ:CLVS) announces its next round of earnings this Tuesday, February 23. Here is Benzinga's everything-that-matters guide for thi... |
The Week Ahead In Biotech: J&J Vaccine A... | 02/20/21 |
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pa... |
Clovis Oncology to Announce Fourth Quart... | 02/17/21 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results o... |
Clovis Oncology Presents Data in Advance... | 02/11/21 |
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting |
PARP Inhibitor Market Covid19 Impact - A... | 02/08/21 |
Coherent Market Insights announced that it???s published an exclusive report namely Global PARP Inhibitor Market by Manufacturers, Regions, Type, and ... |
$CLVS #CLOVISONCOLOGY - Stocks Rebounded... | 02/03/21 |
STATE OF THE MARKETS Stocks rebounded on stimulus hope. US equities rebounded on optimism over new stimulus spending to revive the world???s largest e... |
Global Ovarian Cancer Drug Market Trends... | 02/02/21 |
Global Ovarian Cancer Drug market report gives essential information, objective insights regarding international market trends and leads, competitor a... |
Clovis Oncology Announces Preliminary Pr... | 01/11/21 |
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece |
Global Ovarian Cancer Drug Market Growth... | 12/29/20 |
According to the Ovarian Cancer Drug Market report, the global market is expected to witness a relatively higher growth rate during the forecast perio... |
Clovis Oncology Submits Investigational ... | 12/29/20 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Inves... |
Ovarian Cancer Disease Insights and Mark... | 12/16/20 |
DUBLIN--(BUSINESS WIRE)--The "Ovarian Cancer - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offeri... |
Clovis Oncology Announces Exercise by Ex... | 11/24/20 |
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Prin... |
Zacks: Brokerages Expect Clovis Oncology... | 11/18/20 |
Equities analysts predict that Clovis Oncology (NASDAQ:CLVS) will announce earnings of ($0.81) per share for the current fiscal quarter, according to ... |
Clovis Oncology (NASDAQ:CLVS) Receives $... | 11/16/20 |
Clovis Oncology (NASDAQ:CLVS) has been given a consensus rating of ???Hold??? by the ten ratings firms that are covering the company, Marketbeat Ratin... |
Clovis Oncology Announces Third Quarter ... | 11/05/20 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, an... |
Clovis Oncology Announces Debt Exchange ... | 11/05/20 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes |
Clovis Oncology (NASDAQ:CLVS) Given Aver... | 10/24/20 |
Clovis Oncology (NASDAQ:CLVS) has been assigned an average rating of ???Hold??? from the eleven research firms that are presently covering the firm, M... |
Brokerages Expect Clovis Oncology (NASDA... | 10/24/20 |
Analysts expect Clovis Oncology (NASDAQ:CLVS) to announce sales of $42.34 million for the current fiscal quarter, Zacks Investment Research reports. F... |
Clovis Oncology (NASDAQ:CLVS) Expected t... | 10/23/20 |
Equities research analysts expect that Clovis Oncology (NASDAQ:CLVS) will announce $42.34 million in sales for the current fiscal quarter, Zacks repor... |
Global Ovarian Cancer Drug Market 2020 G... | 10/15/20 |
???Global Ovarian Cancer Drug Market???Industry Trends and Forecast to 2026??? New Research Report Added to Databridgemarketresearch.com database. The... |
Clovis Oncology Announces Oral Plenary S... | 09/10/20 |
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digita... |
Clovis Oncology to Highlight Data for it... | 09/09/20 |
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 |
FDA OKs FoundationOne CDx as a companion... | 08/27/20 |
Clovis Oncology (NASDAQ:CLVS) announces that the FDA has approved Roche (OTCQX:RHHBY) unit Foundation Medicine???s FoundationOne Liquid CDx, a liquid ... |
FDA Approves FoundationOne?? Liquid CDx ... | 08/26/20 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--FDA Approves FoundationOne?? Liquid CDx to Serve as Rubraca?? (rucaparib) Companion Diagnostic to Identify ... |
Why Clovis Oncology's Stock Is Trading H... | 08/17/20 |
Clovis Oncology (NASDAQ:CVLS) shares are trading higher on Monday after the Journal Of Clinical Oncology published data from the Phase 2 TRITON2 study... |
Journal of Clinical Oncology Publishes A... | 08/17/20 |
BOULDER, Colo.--(BUSINESS WIRE)--JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca?? for the Treatment of mCRPC in Pat... |
Date | 2021-02-23 (AMC) | Est. (EPS/Rev.) | ($0.77)/ 43.22M |
Actual (EPS/Rev.) | $-0.74/ $43.30 M | EPS (TTM) | 0 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
WIDE AWAKE | JOHN KROLIKOWSKI JR | 81.00 % | Follow |
Alpha Swing Trades | Jonathan | 68.00 % | Follow |
smashingdon | Paul | 63.00 % | Follow |
Best Trading Ideas | Best Trading Ideas | 54.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.